BetterLife Pharma Inc. (BETRF)
OTC PINK 
Summary
BetterLife Pharma Inc. (BETRF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BetterLife Pharma Inc. ever had a stock split?
BetterLife Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ahmad Doroudian CEO | OTC PINK Exchange | 08772P202 CUSIP |
| CA Country | 7 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BetterLife Pharma Inc. is a Canadian biotechnology company dedicated to the development of novel compounds for treating various mental disorders. Initially known as Pivot Pharmaceuticals Inc., the company underwent a name change to BetterLife Pharma Inc. in December 2019, marking a new chapter in its mission. Since its inception in 2002, BetterLife Pharma Inc. has been actively engaged in the exploration of interferon-based technologies aimed at activating the immune system to combat viral infections. With its headquarters in Vancouver, Canada, BetterLife Pharma is at the forefront of biotechnological research, striving to address unmet medical needs in the realms of neuro-psychiatric, neurological disorders, and infectious diseases.
Products and Services
- BETR-001
- BETR-002
- MM-003
- MM-001
Designed for individuals suffering from major depressive disorder, anxiety, neuropathic pain, and other neuro-psychiatric and neurological disorders, BETR-001 is a flagship product of BetterLife Pharma. This compound is currently under various stages of development, aiming to provide relief and improve the quality of life for patients dealing with these conditions.
BetterLife Pharma is also developing BETR-002, which targets the treatment of benzodiazepine dependency, anxiety, and neurodegenerative disorders. This innovative compound represents the company's commitment to finding solutions for conditions that significantly affect patients' day-to-day lives and mental health.
MM-003 has completed Phase II clinical trials and is a testament to BetterLife Pharma’s dedication to fighting respiratory viral infections, including COVID-19. This product underscores the company’s efforts in leveraging its immune system-engaging interferon-based technologies against viral pathogens, showcasing a potential broader application in infectious diseases.
A topical cream that has finished Phase II clinical trials for local intravaginal use, MM-001 is designed to treat HPV-induced cervical intraepithelial neoplasia. This development highlights BetterLife Pharma’s commitment to expanding its research and development efforts beyond neuro-psychiatric disorders to include solutions for viral-induced conditions.
